Results 71 to 80 of about 3,850,355 (295)

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Cancer Discovery, 2016
UNLABELLED Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with ...
Pei-Ling Chen, Whijae Roh, A. Reuben, Z. Cooper, C. Spencer, P. Prieto, John P Miller, R. Bassett, V. Gopalakrishnan, K. Wani, M. P. de Macedo, J. Austin-Breneman, Hong Jiang, Q. Chang, S. Reddy, Wei-Shen Chen, M. Tetzlaff, R. Broaddus, M. Davies, J. Gershenwald, L. Haydu, A. Lazar, S. Patel, P. Hwu, W. Hwu, A. Diab, I. Glitza, S. Woodman, L. Vence, I. Wistuba, R. Amaria, L. Kwong, V. Prieto, R. Davis, Wencai Ma, W. Overwijk, A. Sharpe, Jianhua Hu, P. Futreal, J. Blando, Padmanee Sharma, J. Allison, L. Chin, J. Wargo   +43 more
semanticscholar   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Imaging Key Biomarkers of Tumor Angiogenesis [PDF]

Theranostics, 2012
Angiogenesis is a fundamental requirement for tumor growth and therefore it is a primary target for anti-cancer therapy. Molecular imaging of angiogenesis may provide novel opportunities for early diagnostic and for image-guided optimization and management of therapeutic regimens.
Joseph M. Backer, Marina V. Backer
openaire   +3 more sources

Sex-specific alterations in functional connectivity and network topology in patients with degenerative cervical myelopathy

Scientific Reports
Patients with degenerative cervical myelopathy (DCM) experience structural and functional brain reorganization. However, few studies have investigated the influence of sex on cerebral alterations.
Talia C. Oughourlian, Shan Rizvi, Chencai Wang, Alex Kostiuk, Noriko Salamon, Langston T. Holly, Benjamin M. Ellingson   +6 more
doaj   +1 more source

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

Breast Cancer Research, 2020
Purpose Previous cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC).
Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy, François-Clément Bidard   +13 more
doaj   +1 more source

Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets

Frontiers in Cell and Developmental Biology, 2021
Neuroblastoma is a type of cancer intimately related with early development and differentiation of neuroendocrine cells, and constitutes one of the pediatric cancers with higher incidence and mortality.
Caroline E. Nunes-Xavier, Caroline E. Nunes-Xavier, Laura Zaldumbide, Lorena Mosteiro, Ricardo López-Almaraz, Nagore García de Andoin, Pablo Aguirre, Maite Emaldi, Leire Torices, José I. López, José I. López, Rafael Pulido, Rafael Pulido   +12 more
doaj   +1 more source

Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer

Journal of Breast Cancer, 2019
Purpose Tumor-associated macrophages (TAMs) are activated macrophages associated with tumor progression in various cancers. TAMs can polarize M1 or M2 type. M1 has a pro-inflammatory function and kills pathogens.
H. Jeong, I. Hwang, S. Kang, Hyeong Chan Shin, S. Kwon   +4 more
semanticscholar   +1 more source

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source

Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma

CNS Oncology
Aim: A radio-pathomic machine learning (ML) model has been developed to estimate tumor cell density, cytoplasm density (Cyt) and extracellular fluid density (ECF) from multimodal MR images and autopsy pathology.
Sonoko Oshima, Jingwen Yao, Samuel Bobholz, Raksha Nagaraj, Catalina Raymond, Ashley Teraishi, Anna-Marie Guenther, Asher Kim, Francesco Sanvito, Nicholas S Cho, Blaine S. C. Eldred, Jennifer M Connelly, Phioanh L Nghiemphu, Albert Lai, Noriko Salamon, Timothy F Cloughesy, Peter S LaViolette, Benjamin M Ellingson   +17 more
doaj   +1 more source

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Journal of Immunotherapy for Cancer, 2018
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma.
Jason Zhu, A. Armstrong, T. Friedlander, W. Kim, S. Pal, D. George, Tian Zhang   +6 more
semanticscholar   +1 more source